NewsCannabis 3.0: Data, Institutional Investors And Cannabis As An...

Cannabis 3.0: Data, Institutional Investors And Cannabis As An Ingredient – Not The Product

-

THE cannabis industry is entering a new phase – Cannabis 3.0 – which will see an end to prohibition and a shift to cannabis being treated as an ingredient not the product itself.

This, combined with the arrival of the major Consumer Packaged Goods (CPG) companies and executives, will shift the focus to delivering the data required to support growth.

Owen Bennett, of Jefferies Financial Group.

And, this is now providing a ‘once in a generation wealth opportunity’ for investors, delegates to the Global Cannabis Intelligence Virtual Summit, heard.

Cannabis 1.0, the emergence of a legal cannabis industry in North America, over the last decade, leaves a legacy ‘poorly-run companies’ and out-of- pocket investors, said Owen Bennett, of Jefferies Financial Group.

When Money Was Cheap

In a session entitled: ‘Capital Markets Outlook & What We Need To See For More Institutional Investment’ he estimated the global industry being worth somewhere between $50bn and $140bn by the end of the decade.

He said that while some see cannabis as a bubble, similar to Bitcoin, he  believes it is more apt to relate it to the growth of the tech sector.

He said: “Following the Dotcom boom and bust technology stocks have grown steadily, and this is what will happen with cannabis. In fact what is  more exciting with cannabis is that the market already exists – in the illicit sector – and this was not the case with tech.”

Cannabis needs greater institutional investment to support its growth, however, some sector-specific issues need to be resolved before this happens.

“One of the issues in the cannabis space is the existence of many companies that should not be around. They created a business when money was easy and many of these did not have a proper business model. Simply saying they were cannabis, allowed them to get retail money.”

He went on to say many early management teams were good at raising money but not running CPG businesses. 

Generational Wealth Opportunity

“Very few are now making money and this creates risks for the institutions investing in the space.” 

With the capital markets currently tight for cannabis many under-pressure firms are now turning to the debt markets at ‘unfavourable terms’. 

“This will see the some businesses go bankrupt and clear the way for the entry of better companies,” he said.

Jeffries foresees two years of consistent sales growth and profitability and this improving picture will attract more CPG companies and similarly deliver greater confidence on execution to the institutions.

“The biggest boost to the institutions is legislation and with the US Elections there has been a great shift in this direction, providing a generational wealth opportunity,” he concluded. 

An Ingredient Not The Product

This theme was taken up by Narbe Alexandrian, of Canopy Rivers, in a session entitled: The Path to Cannabis 3.0.

Cannabis 2.0 was the launch of cannabis derivates such as edibles in Canada last year following initial legalisation in 2018.

Mr Alexandrian said: “The end of cannabis prohibition across multiple geographies will open up the industry to R&D and  financial activities such as banking and insurance which we take for granted in other industries.”

A second key theme is evolution of cannabis as an ingredient, not as end product in itself.

He said: “Many companies are building cannabis products as the be-all and end-all, however cannabis, the cannabinoids the terpenes are merely an ingredient in what you are trying to create.

“Instead of creating a cannabis product that is good for sleep why not create a sleep product that includes cannabinoids and other ingredients so you can hit the pain points of what consumers are looking for?”

His third key takeaway was the arrival of the CPG businesses and established brands start to secure a foothold in the marketplace.

One further development will be the increasing reliance on data to support the industry’s growth.

He added: “There is a lack of data with the roll out of cannabis 3.0, data will proliferate and the companies with first access to this will be the ones to lead the way.”


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

New French Hemp Rules Under-fire Over Proposals To Outlaw CBD Flowers

THE French government is pressing ahead with moves to outlaw the sale of CBD flowers despite recent decisions to...

UK CBD Brand OTO Signs Deal With Synthetic CBD Brand Pureform Global

LONDON-based wellness and CBD brand, OTO, have signed a partnership deal with Pureform Global. This groundbreaking partnership will enable...

Significant Year-On-Year Rise In German Medical Cannabis Flower Imports

DESPITE a decline in cannabis flower imports for the first quarter of 2021 the German medical cannabis market continues...

Low-Cost Medical Cannabis Flowers To Be Exported From Colombia For The First Time

COLOMBIA is set to permit the export of medical cannabis flower for the first time in what could be...

UK Cannabis Business Eco Equity Announces 100% Equity Acquisition By US Firm Virtual Medical International

ECO Equity Limited a UK company with cultivation assets in Africa, will combine its operations with Virtual Medical International...

New Amendments Could Delay Passing Of Greek Medical Cannabis Bill Until Next Year

GREEK businesses are preparing for amendments to the Mediterranean country’s cannabis laws allowing the cultivation, sale and export of...

Must read

New French Hemp Rules Under-fire Over Proposals To Outlaw CBD Flowers

THE French government is pressing ahead with moves to...

Low-Cost Medical Cannabis Flowers To Be Exported From Colombia For The First Time

COLOMBIA is set to permit the export of medical...

You might also likeRELATED
Recommended to you